Literature DB >> 20605791

Internal cleavages of the autoinhibitory prodomain are required for membrane type 1 matrix metalloproteinase activation, although furin cleavage alone generates inactive proteinase.

Vladislav S Golubkov1, Piotr Cieplak, Alexei V Chekanov, Boris I Ratnikov, Alexander E Aleshin, Natalya V Golubkova, Tatiana I Postnova, Ilian A Radichev, Dmitri V Rozanov, Wenhong Zhu, Khatereh Motamedchaboki, Alex Y Strongin.   

Abstract

The functional activity of invasion-promoting membrane type 1 matrix metalloproteinase (MT1-MMP) is elevated in cancer. This elevated activity promotes cancer cell migration, invasion, and metastasis. MT1-MMP is synthesized as a zymogen, the latency of which is maintained by its prodomain. Excision by furin was considered sufficient for the prodomain release and MT1-MMP activation. We determined, however, that the full-length intact prodomain released by furin alone is a potent autoinhibitor of MT1-MMP. Additional MMP cleavages within the prodomain sequence are required to release the MT1-MMP enzyme activity. Using mutagenesis of the prodomain sequence and mass spectrometry analysis of the prodomain fragments, we demonstrated that the intradomain cleavage of the PGD/L(50) site initiates the MT1-MMP activation, whereas the (108)RRKR(111)/Y(112) cleavage by furin completes the removal and the degradation of the autoinhibitory prodomain and the liberation of the functional activity of the emerging enzyme of MT1-MMP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20605791      PMCID: PMC2934640          DOI: 10.1074/jbc.M110.135442

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2.

Authors:  H Sato; T Kinoshita; T Takino; K Nakayama; M Seiki
Journal:  FEBS Lett       Date:  1996-09-09       Impact factor: 4.124

2.  The recombinant catalytic domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) induces activation of progelatinase A and progelatinase A complexed with TIMP-2.

Authors:  A Lichte; H Kolkenbrock; H Tschesche
Journal:  FEBS Lett       Date:  1996-11-18       Impact factor: 4.124

3.  The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3.

Authors:  H Will; S J Atkinson; G S Butler; B Smith; G Murphy
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

4.  Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.

Authors:  C Fernandez-Catalan; W Bode; R Huber; D Turk; J J Calvete; A Lichte; H Tschesche; K Maskos
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

5.  Peptides based on the conserved predomain sequence of matrix metalloproteinases inhibit human stromelysin and collagenase.

Authors:  A C Hanglow; A Lugo; R Walsky; M Finch-Arietta; L Lusch; M Visnick; N Fotouhi
Journal:  Agents Actions       Date:  1993

6.  Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin).

Authors:  A E Mast; J J Enghild; H Nagase; K Suzuki; S V Pizzo; G Salvesen
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

7.  Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease.

Authors:  A Y Strongin; I Collier; G Bannikov; B L Marmer; G A Grant; G I Goldberg
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

8.  Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme.

Authors:  J W Becker; A I Marcy; L L Rokosz; M G Axel; J J Burbaum; P M Fitzgerald; P M Cameron; C K Esser; W K Hagmann; J D Hermes
Journal:  Protein Sci       Date:  1995-10       Impact factor: 6.725

9.  Potent peptide inhibitors of stromelysin based on the prodomain region of matrix metalloproteinases.

Authors:  N Fotouhi; A Lugo; M Visnick; L Lusch; R Walsky; J W Coffey; A C Hanglow
Journal:  J Biol Chem       Date:  1994-12-02       Impact factor: 5.157

10.  Furin-dependent intracellular activation of the human stromelysin-3 zymogen.

Authors:  D Pei; S J Weiss
Journal:  Nature       Date:  1995-05-18       Impact factor: 49.962

View more
  12 in total

1.  Potential relation of aberrant proteolysis of human protein tyrosine kinase 7 (PTK7) chuzhoi by membrane type 1 matrix metalloproteinase (MT1-MMP) to congenital defects.

Authors:  Vladislav S Golubkov; Alexander E Aleshin; Alex Y Strongin
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

2.  Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth.

Authors:  Albert G Remacle; Vladislav S Golubkov; Sergey A Shiryaev; Russell Dahl; John L Stebbins; Andrei V Chernov; Anton V Cheltsov; Maurizio Pellecchia; Alex Y Strongin
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

3.  Intradomain cleavage of inhibitory prodomain is essential to protumorigenic function of membrane type-1 matrix metalloproteinase (MT1-MMP) in vivo.

Authors:  Vladislav S Golubkov; Andrei V Chernov; Alex Y Strongin
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

4.  The Functional Maturation of A Disintegrin and Metalloproteinase (ADAM) 9, 10, and 17 Requires Processing at a Newly Identified Proprotein Convertase (PC) Cleavage Site.

Authors:  Eitan Wong; Thorsten Maretzky; Yoav Peleg; Carl P Blobel; Irit Sagi
Journal:  J Biol Chem       Date:  2015-03-20       Impact factor: 5.157

5.  The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly efficient proteolytic target of membrane type-1 matrix metalloproteinase: implications in cancer and embryogenesis.

Authors:  Vladislav S Golubkov; Alexei V Chekanov; Piotr Cieplak; Alexander E Aleshin; Andrei V Chernov; Wenhong Zhu; Ilian A Radichev; Danhua Zhang; P Duc Dong; Alex Y Strongin
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

6.  A role for MT1-MMP as a cell death sensor/effector through the regulation of endoplasmic reticulum stress in U87 glioblastoma cells.

Authors:  Sébastien Proulx-Bonneau; Jonathan Pratt; Borhane Annabi
Journal:  J Neurooncol       Date:  2010-11-19       Impact factor: 4.130

7.  Predictive models of protease specificity based on quantitative protease-activity profiling data.

Authors:  Gennady G Fedonin; Alexey Eroshkin; Piotr Cieplak; Evgenii V Matveev; Gennady V Ponomarev; Mikhail S Gelfand; Boris I Ratnikov; Marat D Kazanov
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2019-07-19       Impact factor: 3.036

8.  Epigenetic regulation of matrix metalloproteinases and their collagen substrates in cancer.

Authors:  Andrei V Chernov; Alex Y Strongin
Journal:  Biomol Concepts       Date:  2011-06

Review 9.  Matrix Metalloproteinases in Chemoresistance: Regulatory Roles, Molecular Interactions, and Potential Inhibitors.

Authors:  Bernadette Xin Jie Tune; Maw Shin Sim; Chit Laa Poh; Rhanye Mac Guad; Choy Ker Woon; Iswar Hazarika; Anju Das; Subash C B Gopinath; Mariappan Rajan; Mahendran Sekar; Vetriselvan Subramaniyan; Neeraj Kumar Fuloria; Shivkanya Fuloria; Kalaivani Batumalaie; Yuan Seng Wu
Journal:  J Oncol       Date:  2022-05-09       Impact factor: 4.501

10.  Non-destructive and selective imaging of the functionally active, pro-invasive membrane type-1 matrix metalloproteinase (MT1-MMP) enzyme in cancer cells.

Authors:  Albert G Remacle; Sergey A Shiryaev; Vladislav S Golubkov; John N Freskos; Michael A Brown; Amolkumar S Karwa; Arati D Naik; Carol P Howard; Carolyn J Sympson; Alex Y Strongin
Journal:  J Biol Chem       Date:  2013-06-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.